This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Professor Peter
van der Meer, MD, PhD
UMCG Cardiology research institute, Groningen, UThe Netherlands

Peter van der Meer received both his MD and PhD cum laude from the University of Groningen in the Netherlands. He is trained as a cardiologist with a focus on heart failure and cardiac devices. He did a postdoctoral fellowship at Harvard Medical School with prof. Ken Chien to further train his skills in cardiac stem cell biology.

The group of Prof. Van der Meer consists of PhD students, technicians and post-docs with various backgrounds (biologists, medical doctors, and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. His group focuses on understanding the susceptibility to develop heart failure and exploring novel treatment targets and therapies. He is a member of several steering committees of large morbidity and mortality trials investigating the impact of new and old drugs in patients with heart failure, including digoxin and iron.